Axogen, Inc. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Axogen reported Q3 2026 revenue of $75.8M (+26.2% YoY) and raised full-year 2026 guidance to at least $290M (≥29% growth), including ≥$7M from BioCircuit. The company completed acquisition of BioCircuit Technologies on October 1, 2026, funding it with $225M net proceeds from an upsized public offering of 5,646,500 shares. Cash position increased $236.7M to $350.1M (Sep 30, 2026). The company also paid off long-term debt (~$48.6M) and incurred $16.8M loss on debt extinguishment in 9M 2026. Additionally, Axogen announced entry into prostate market development starting 2027 based on positive clinical outcomes (220+ procedures at 15 sites).
Why this rating
BioCircuit acquisition (~$200M, 46% of market cap) is meaningful M&A, combined with debt payoff, strong revenue growth (+26% organic), margin expansion, and new prostate market. Mixed: debt refinancing cost ($16.8M loss) and dilution from 5.6M share issuance partially offset gains.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.